Immunotech Laboratories, Inc.

(A Development Stage Company)

Issuer's Initial Disclosure Statement

July 3, 2014, 2014

(OTC Pink: IMMB) OTC Pink

We previously were a shell company, therefore the safe harbor provided by Rule 144 is not readily until one year after we posted "Form 10"information. Anyone who purchased securities directly or indirectly from us or any of our affiliates in a transaction or chain of transactions not involving a public offering may not be able to sell such securities in an open market transaction.

Table of Contents

Table of Contents Cont.

Part. A General Company Information

Item 1. Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past **five**

years and the dates of the name changes.

Immunotech Laboratories, Inc., a Nevada corporation (hereinafter referred to as the "Company", "we", "us", or "our" or "the Issuer").

a) Incorporated in the State of Nevada on April 11, 2000 under the name of "Earthnet Media.com".

b) On April 8, 2001, changed its name to "Earthnet Media,Inc."

c) On October 18, 2006, changed its name to "International Technology Systems, Inc." and traded under the symbol ITYS

d) On December 15, 2008, the Company effected a reverse merger with Immunotech Laboratories, Inc. and on December 18, 2008 changed its name to Immunotech Laboratories, Inc. trading under the symbol IMMB.

Item 2. Address of the issuer's principal executive offices

Company Headquarters Address:

120 W Pomona Ave

Monrovia, CA 91016

Phone: (818) 409-9091

Fax: (626) 703-4172

Email: info@immunotechlab.com

Website: http//www.immunotechlab.com

Item 3. The jurisdiction(s) and date of the issuer's incorporation or organization

Incorporated in the State of Nevada on April 11, 2000

Part B Share Structure.

Item 4. The exact title and class of securities outstanding

CUSIP Number: 45254f203

Trading Symbol: IMMB

Common Stock Outstanding: 452,518,547

Restricted Common Stock: 418,668,155

Preferred A Stock Outstanding: 50,000,000

Preferred B Stock Outstanding: 200,000,000

Item 5. Par or stated value and description of the security

A. Par or Stated Value. Provide the par or stated value for each class of outstanding securities.

Exact title and class of securities outstanding: Common Stock

Par or Stated Value: $0.001

Total shares authorized: 800,000,000 as of: March 31, 2014

Additional class of securities (if necessary):

Exact title and class of securities outstanding: Series A Convertible Preferred Stock

Par or Stated Value: $0.001

Total shares authorized: 50,000,000 as of: March 31, 2014

Exact title and class of securities outstanding: Series B Convertible Preferred Stock

Par or Stated Value: $0.001

Total shares authorized: 200,000,000 as of: March 31, 2014

B. Common or Preferred Stock.

1. For common equity, describe any dividend, voting and preemption rights.

None

2. For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.

Holders of Preferred Series A are entitled to one vote per share and are convertible on a 1,000 : 1 share basis.

Holders of Preferred Series B are entitled to 10 : 1 votes per share and are non-convertible on a 1 : 1 basis..

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any provision in the issuer's charter or by-laws that would delay, defer or prevent a change in control of the issuer.

The Company's Articles of Incorporation may be amended to provide that the Board of Directors has the authority to divide the Preferred Stock into series and, within the limitations provided by Nevada statute, to fix by resolution the voting power, designations, preferences, and relative participation, special rights, and the qualifications, limitations or restrictions of the shares of any series so established. The Company anticipates that the Board of Directors may authorize the issuance of Preferred Stock, without shareholder approval, in order to defend against any attempted takeover of the Company.

Item 6. The number of shares or total amount of the securities outstanding for each class of securities authorized

In answering this item, provide the information below for each class of securities authorized. Please provide this information (i) as of the end of the issuer's most recent fiscal quarter and (ii) as of the end of the issuer's last two fiscal years.

(i). Period end date;

See Chart below for Quarter Ended March 31, 2014, Years Ending December 31, 2013 and 2012

(ii). Number of shares authorized;

Common Shares Authorized 800,000,000

Preferred Series A Authorized 50,000,000

Preferred Series B Authorized 200,000,000

(iii). Number of shares outstanding;

Common Shares Issued as of 3-31-2014 452,818,547

Preferred Series A Issued as of 3-31-2014 50,000,000

Preferred Series B Issued as of 3-31-2014 200,000,000

(iv). Freely tradable shares (public float); 33.850,392

(v) Affirmation that the number of beneficial shareholders owning at least 100 shares exceeds 50 or 100, as applicable.

The number of shareholders owning over 100 shares of common stock exceeds 100 at March 31, 2014.

and;

(vi) Total number of shareholders of record. As of March 31, 2014 there are 241 shareholders of record.

Immunotech Laboratories, Inc.
(Formally International Technology Systems, Inc.)
For the Years Ending December 31, 2013 and December 31, 2012 and Quarter ended March 31, 2014

Item	Preferred Series A Par Value $.001	Preferred Series B Par Value $.001	Common Stock Par Value $.001
Balance at December 31, 2012	50,000,000	200,000,000	433,496,325
Shares Issued in 2013			19,322,222
Balance at December 31, 2013	50,000,000	200,000,000	452,818,547
Balance at March 31, 2014	50,000,000	200,000,000	452,818,547

Item 7. The name and address of the transfer agent*

Transfer Agent Name: Pacific Stock Transfer Company Address 1: 4045 South Spencer Street, Suite 403 Address 2: Las Vegas, NV 89119 Address 3: Phone: (702) 361-3033

Is the Transfer Agent registered under the Exchange Act? Yes: X No:

List any restrictions on the transfer of security: None

Part C Business Information

Item 8. The nature of the issuer's business. See written summary at end of questions.

In describing the issuer's business, please provide the following information:

A. Business Development. Describe the development of the issuer and material events during the last **three** years so that a potential investor can clearly understand the history and development of the business. If the issuer has not been in business for three years, provide this information for any predecessor company. This business development description must also include:

1. the form of organization of the issuer (e.g., corporation, partnership, limited liability company, etc.);

Immunotech is a Nevada Coporation

2. the year that the issuer (or any predecessor) was organized;

The Company was organized on April 11, 2000

3. the issuer's fiscal year end date;

December 31 year end

4. whether the issuer (**or any predecessor**) has been in bankruptcy, receivership or any similar proceeding;

None

5. any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets;

None in the last three years

On June 1, 2000 the Company acquired all of the assets of Pac Pacific Group International, Inc. for 5,257,000 common shares.

On April 18, 2001 the Company changed its name from Earthnet Media.com, Inc. to Earthnet Media, Inc.

On February 19, 2006 the Company effected a reverse merger with Callaci Consulting Service, Inc. wherein the Company acquired 100% of the shares of Callaci Consulting in exchange for issuance of 10,306,521 common shares.

On June 21, 2006 the Company approved a forward split of five common shares for one common share thereby increasing the number of outstanding shares from 25,425,573 to 127,425,865.

On October 18, 2006 the Company changed its name to International Technology Systems, Inc.

On March 20, 2007 the Company entered into a Termination/Rescission Agreement with Callaci Consulting Services, Inc. terminating the reverse merger of February 19, 2006.

On December 15, 2008 Immunotech Laboratories, Inc. entered into a reverse merger with Immunotech Laboratories, Inc. of California. The transaction involved the exchange of 100% of the issued and

outstanding common shares of Immunotech California in exchange for 40,000,000 common shares of Immunotech Laboratories, Inc. the Nevada publicly traded entity.

On December 18, 2008 the Company changed its name from International Technology Systems, Inc. to Immunotech Laboratories, Inc.

On January 30, 2009 the Company entered into a licensing agreement with Ara Ghanime and Harry Zhabilov wherein the Company received a license from the Zhabilov Trust for use of the patents underlying use of IPF in treatment of HIV/AIDS only. The licensing agreement provides for Ara Ghanime and Harry Zhabilov to receive 41.5% each of an interest in Immunotech Laboratories, Inc.

On February 26, 2009 the Company effected a one for one hundred reverse split on its common shares reducing the total issued and outstanding common shares from 55,566,022 to 555,660 common shares.

6. any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;

None

7. any change of control;

On September 14, 2012 Series B Preferred Shares totaling 190,000,000 with voting rights of 10 : 1 were issued to Harry Zhabilov giving him voting control

8. any increase of 10% or more of the same class of outstanding equity securities;

Immunotech Laboratories, Inc. was incorporated under the laws of the State of Nevada on April 11, 2000 as Earthnet Media.com, Inc., the Company's Articles of Incorporation provide for authorized capital of 25,000,000 Common shares, at a par value of $0.001 per share.

On October 1, 2000 the Company increased its authorized capital from 25,000,000 common shares to 50,000,000 common shares with a par value of $0.001 per share.

On February 27, 2003 the Company increased its capital stock from 50,000,000 common shares to 100,000,000 common shares with par value of $0.001 per share.

On June 23, 2005 the Company increased the authorized common shares to 150,000,000 with par value of $0.001 per share and created a Preferred Class of 50,000,000 Series A with par value of $0.001 per share.

Events occurring within the last three years

In the calendar year 2012 the Company increased the authorized common shares to 800,000,000 with par value of $0.001 per share.

On September 14, 2014 the Company created a Preferred Class of 200,000,000 Series B with par value of $0.001 per share.

9. any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization;

None in the last three years

On February 19, 2006 the Company entered into a reverse merger agreement with Callaci Consulting, Inc.

On June 21, 2006 the Company effectuated a 5:1 forward reverse.

On March 20, 2007 the Company entered into a rescission Agreement terminating the reverse merger with Callaci Consulting, Inc.

On February 26, 2009 the Company effectuated a 100 : 1 reverse

On December 15, 2008 the Company entered into a reverse merger agreement with Immuntech California, Inc.

10. any delisting of the issuer's securities by any securities exchange or deletion from the OTC Bulletin Board; and

None

11. any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations and any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.

None

B. Business of Issuer. Describe the issuer's business so a potential investor can clearly understand it. To the extent material to an understanding of the issuer, please also include the following:

1. the issuer's primary and secondary SIC Codes;

The Company's primary SIC Code is 541711.

The Company's Secondary SIC Code is 541990.

2. if the issuer has never conducted operations, is in the development stage, or is currently conducting operations;

The Company is currently in the research and development stage of operations and is in the process of finalizing field test and starting Clinical test through a Bulgarian subsidiary of which the Company owns 49%.

3. whether the issuer has at any time been a "shell company**";**

The Company prior to 12-31 2006 checked the box indicating it was a Shell Company. We ceased to be a shell company upon the completion of our merger with Immunotech Laboratories. We filed our form 10 information with the Securities and Exchange Commission on January 5,2011when we filed our form 10-K for the period ending December 31, 2009. In November of 2013 the Company announced its change in shell status. The Company is currently not a Shell Company.

Instruction to paragraph B.3 of Item 8:

4. the names of any parent, subsidiary, or affiliate of the issuer, and its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure statement;.

The Company is a 49% owner of Immunotech Laboratories BG a company organized on October 11, 2012 under the laws of the Country of Bulgaria. This entity was organized to conduct Clinical trials of the Company's treatments on twenty patients in Bulgaria. The Investment is recorded on the balance sheet as of December 31, 2013 and March 31, 2014. The operations are not consolidated with the Company's results of operation. The Company is holder of exclusive licensing agreement of the US patent numbers 7,479,538 and 8,066,982. Immunotech Laboratories BG is the vehicle that the Company is attempting to commercialize the treatments developed under these patents in Bulgaria.

5. the effect of existing or probable governmental regulations on the business;

FDA approval process is based on The Food and Drug Administration's Strategic Action Plan for Risk Communication is an initiative to tell consumers how the agency makes decisions on the safety and effectiveness of FDA-regulated products. This is the first in a series of articles about the data and methods—and their limitations—that FDA uses to determine whether products are safe for patients and consumers to use.

This is how the agency's Center for Drug Evaluation and Research evaluates the safety and effectiveness of drugs.

The Regulation of Drugs How the Facts Are Collected

1- The first step for a company seeking approval to sell a new drug is to perform laboratory and animal tests to learn how the drug works and if it will be safe enough to be tested in humans. The company submits an Investigational New Drug Application (IND) for FDA's review prior to testing in humans.
2- The company performs a series of clinical trials in humans in three phases, which FDA monitors, to test if the drug is effective and safe.
3- Next, the company sends its data from all these tests to FDA's Center for Drug Evaluation and Research (CDER) in a New Drug Application (NDA). A team of CDER physicians, statisticians, toxicologists, pharmacologists, chemists and other scientists review the data and proposed labeling.
4- If this review establishes that a drug's benefits outweigh its known risks for its proposed use, the drug is approved for sale.
5- After the drug is on the market, the FDA monitors its performance in a number of ways. One of those ways is the through MedWatch, the agency's safety information and adverse event reporting program, which receives reports of suspected adverse reactions (side effects of medicines) from consumers, health care practitioners and pharmaceutical companies. And the agency has access to databases that collect information on prescription drug use and health outcomes. These data help FDA staff identify and understand side effects of medicines.

If an unexpected drug-related health risk is detected, a Drug Safety Communication may be issued to consumers and healthcare professionals. A statement is added to the drug label about the new safety concern to ensure continued safe and effective use of the drug. Occasionally, approved drugs may be withdrawn from the market for serious safety risks if it is determined that the overall risks outweigh any benefits the drug may provide.

6. an estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

During the Calendar years ending December 31, 2013 and December 31, 2012 the Company incurred $250,000 and $75,000 of cost associated with its research and development efforts that were borne by the Company. No cost were paid by Customers as the Company's treatments have not been approved by the FDA for use.

7. costs and effects of compliance with environmental laws (federal, state and local);

None. The Company will use a contract manufacturing facility for the drugs and Immunotech will not be a manufacturing facility.

and;

8. the number of total employees and number of full-time employees.

Immunotech employees 1 full time employee, Harry H. Zhaboliv.

Item 9 The nature of products or services offered.

In responding to this item, please describe the following so that a potential investor can clearly understand the products and services of the issuer:

A. principal products or services, and their markets;

Immunotech Laboratories Inc. a Nevada Corporation incorporated on April 11, 2000, is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. The Company is dedicated to the commercialization of these License rights of the IPF for the treatment of Aids and Hepatitis C as well as potential other treatments for life threatening diseases. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus' peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Immunotech Laboratories Inc., in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.

ITV, produced by Immunotech Laboratories, Inc. is a brand new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.

Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 up to 1000 million dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with new comers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching $ 15 billion in year 2012, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost and eventual viral resistance.

In summation our product’s differentiation is based on:

1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation

B. distribution methods of the products or services;

The Company is in the process of conducting Field and clinical test and the product is not being distributed at this point.

C. status of any publicly announced new product or service

Immunotech Laboratories is in the process of commercialization of ITV 1 in USA and EU after following all the existing regulations governed by the countries

D. competitive business conditions, the issuer’s competitive position in the industry, and methods of competition;

ITV, produced by Immunotech Laboratories, Inc. is a brand new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated. The laboratory results obtained from ITV treated patients have shown the following:

1. Increase in WBC after the second week of treatment
2. A Two fold increase in MHC II cell expression as well as an increase in HLA-DR receptor expression after the first week of treatment
3. Increase in gamma/delta chain expression on T-cells after the second week of the treatment and their decrease after fourth weeks
4. A drop in CD4 cell count after the second week and gradual, uninterrupted increase after the third week
5. Dramatic increase in HIV –1 RNA by PcR the second week
6. Two times increasing in IgG after the fourth week

7. Two to tenfold increases in HIV –1 antibodies after the fourth week measured by Western Blot
8. Serum conversion from p24 positive to p24 negative
9. One to two log decrease in HIV –1 RNA by PcR, becoming undetectable one month after the end of the treatment
10. Reduction of HIV-1 infected cells' population as measured by PBMC's to undetectable levels.

The results of the above blood investigation may be interpreted as:

1. Increasing in WBC shows cell stimulation by ITV
2. Increase in MHC II and HLA-DR receptor expression verifies that ITV is being recognized
3. Increasing in gamma/delta expression demonstrates activation of the T-cells antigen receptors. Gamma/delta T-cell receptors share many cell-surface with alpha/beta T-cells and are able to secret lymphokines and express cytolytic activities in response to antigen stimulation.
4. A CD4 decrease after the second week suggests cytolytic activity against CD4 HIV-1 contaminated cells. This observation provides explanation why there is an increase of the serum viral load after the third week
5. The most important result from ITV treatment is a specific anti HIV-1 antibody increase in high levels. We can assume that ITV introduced in the human body binds with a high degree of affinity to gp41 HIV-1 envelop protein and a new build-up of super-antigen elicits antibody production in sufficient quantity to eliminate the viral infection.

Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 up to 1000 million dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with new comers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching $ 15 billion in year 2012, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost and eventual viral resistance.

In summation our product's differentiation is based on:

Minimal and minor side effects
Zero toxicity issues
Tremendous cost savings
Short and limited treatment cycle
Easier Compliance adherence
Zero risk of viral resistance and mutation

E. sources and availability of raw materials and the names of principal suppliers;

The primary raw material is a porcine pepsin provided by Affimetrix. The material is readily available.

F. dependence on one or a few major customers;

The Company is in the development stages of its treatments. It is estimated that there are over 40 million individuals worldwide living with the HIV virus.

G. patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration; and

Immunotech has a strong technology and patent position through its own efforts as well as through in-licensed technology and OEM product development agreements. In total, Immunotech products will be

Title	U.S. Patent Number/Application Number
IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME FOR DETECTING, PREVENTING, AND TREATING HIV	12/321,262
IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME FOR DETECTING, PREVENTING, AND TREATING HIV	7,479,538

protected by numerous issued patents, pending patents and others under preparation. It is anticipated that additional patents will be applied for as the novel products are finalized and then expanded to include additional applications.

The Following are Patents and Patents pending on the treatments being developed by the Company;

Country	Title	Application Number
Canada	IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THIS FRAGMENT FOR DETECTING, PREVENTING, AND TREATING HIV	2,634,589

Hong Kong	IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THIS FRAGMENT FOR DETECTING, PREVENTING, AND TREATING HIV	08102808.0 / us 11/177,427
Mexico		MX/a/2010/001901

Excerpts from Patent Valuation Report:

This PATENT VALUE report was generated by Pantros IP subject to these Notes & Terms .

PF/value Report Number 2010127-7479538

charlesclarke

Patent Number: US 7479538

Patent Title: Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV

PATENT VALUE REPORT

This Patent Value Report separately analyzes the three important factors that IP professionals traditionally use to assess the legal and economic value of an issued US patent. This report is comprised of three primary valuation factors: legal indices, patent value and protected market value.

Although a separate Patent Factor score is provided, all three legal and economic factors are interrelated.

1. Patent Legal Factors

2. Economic Patent Value (as a computed share of the Protected Market)

3. Economic value of the market protected by the patent (as a computed share of the US Gross Domestic Product)

The Patent Value Report Terms (PDF) help interpret the data presented in this report, and are considered an integral part of this

Patent Value Report.

Additional information related to patent economic value as presented in this report is available in Pantros IP's Knowledge base.

PATENT VALUE PROJECTED MARKET SIZE

Estimated Size of Patent Protected Market: $10,493,259.32

PATENT VALUE PROJECTED PATENT VALUATION

Predicted Patent Value: $5,203,874.67

PATENT VALUE LEGAL SUMMARY

Remaining Life of Patent: 15 Years 6 Months

PATENT BIBLIOGRAPHIC DATA

Patent Number: US 7479538

Document Kind: B2

Patent Title: Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIv

Named Inventors: ZHABILOV HARRY H

Applicants (Assignees): ZHABILOV TRUST

Agents: Cislo & Thomas, LLP

Filing Date: 7/11/2005

Issue/Pub Date: 1/20/2009

Patent Termination: Expires: 7/11/2025

Patent Enforceability Status: Enforceable

US Classifications / Sub Classes:

530 / 327

530 / 300

435 / 183

435 / 174

435 / 005

435 / 0071

IPC Classifications / Sub Classes:

A61K / 038/04

A61K / 038/10

A61K / 038/17

C07K / 007/00

C07K / 007/04

C07K / 007/08

G01N / 033/53

Abstract:

An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitrobinding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Patent Family Information:

US2006104992A1 07/11/2005 Enforceable US2009285776A1 06/18/2009 Enforceable

US7479538B2 07/11/2005 Enforceable

H. the need for any government approval of principal products or services and the status of any requested government approvals. At the moment the company follows all regulations required by Bulgarian Drug Agency for acquiring a permit to conduct clinical trial.

Item 10 The nature and extent of the issuer's facilities.

Please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

Immunotech Laboratories, Inc. operates out of a 1,655 sq. ft. facility located in Monrovia, CA in Hamby Industrial Park under a two year lease expiring on March 31, 2015. All lease payments are current under the lease. The President Harry Zhabilov is guarantor on the lease. The Company currently employs 1 full me individual.

Business Plan and Summary

Immunotech Laboratories Inc. a Nevada Corporation incorporated on April 11, 2000, is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus' peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system

components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Immunotech Laboratories Inc., in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.

Immunotech, Laboratories, Inc. is in the developmental stages of its research and development activities. It is a calendar year end corporation. The Immunotech Laboratories, Inc. nor its Predecessors has filed Bankruptcy. The Company has not received any notice of default from any of its lenders but is currently in dispute with a note holder regarding the value accepted as settlement by the lender. The No revenue or sales have been achieved by Immunotech as of yet. Research and development cost are borne by the company. The estimated expenditures for these activities were $250,000 in the year ended December 31, 2013 and $75,000 in the year ended December 31, 2012. Immunotech is not a manufacturing entity and therefore will use a contract manufacturing facility for the drugs which will reduce if not eliminate the cost of Environmental issues.

The Company's mission is the discovery, research and development of innovative and effective drug candidates against a range of life-threatening infectious diseases. Utilizing powerful cell-based high-throughput screening platform complemented with high-content recombinant viral target assays and rational drug design, scientists at Immunotech profile compounds against clinically relevant resistant pathogens. Many pathogens are notorious for their ability to mutate and become resistant to therapy. Therefore, it is vital that new drugs cope with this genetic variability and avoid the emergence of resistance.

The following is a chronological summary of the Company;

On June 1, 2000 the Company acquired all of the assets of Pac Pacific Group International, Inc. for 5,257,000 common shares.

On October 1, 2000 the Company increased its authorized capital from 25,000,000 common shares to 50,000,000 common shares with a par value of $0.001 per share.

On April 18, 2001 the Company changed its name from Earthnet Media.com, Inc. to Earthnet Media, Inc.

On February 27, 2003 the Company increased its capital stock from 50,000,000 common shares to 100,000,000 common shares with par value of $0.001 per share.

On June 23, 2005 the Company changed its name from Earthnet Media, Inc. to International Telecommunications, Inc. and increased the authorized common shares to 150,000,000 with par value of $0.001 per share and created a Preferred Class of 50,000,000 Series A with par value of $0.001 per share.

On February 19, 2006 the Company effected a reverse merger with Callaci Consulting Service, Inc. wherein the Company acquired 100% of the shares of Callaci Consulting in exchange for issuance of 10,306,521 common shares.

On June 21, 2006 the Company approved a forward split of five common shares for one common share thereby increasing the number of outstanding shares from 25,425,573 to 127,425,865.

On October 18, 2006 the Company changed its name to International Technology Systems, Inc.

On March 20, 2007 the Company entered into a Termination/Rescission Agreement with Callaci Consulting Services, Inc. terminating the reverse merger of February 19, 2006.

On December 15, 2008 Immunotech Laboratories, Inc. entered into a reverse merger with Immunotech Laboratories, Inc. of California. The transaction involved the exchange of 100% of the issued and outstanding common shares of Immunotech California in exchange for 40,000,000 common shares of Immunotech Laboratories, Inc. the Nevada publicly traded entity.

On December 18, 2008 the Company changed its name from International Technology Systems, Inc. to Immunotech Laboratories, Inc.

On January 30, 2009 the Company entered into a licensing agreement with Ara Ghanime and Harry Zhabilov wherein the Company received a license from the Zhabilov Trust for use of the patents underlying use of IPF in treatment of HIV/AIDS only. The licensing agreement provides for Ara Ghanime and Harry Zhabilov to receive 41.5% each of an interest in Immunotech Laboratories, Inc.

On February 26, 2009 the Company effected a one for one hundred reverse split on its common shares reducing the total issued and outstanding common shares from 55,566,022 to 555,660 common shares.

In the calendar year 2012 the Company increased the authorized common shares to 800,000,000 with par value of $0.001 per share.

On September 14, 2012 the Company created a Preferred Class of 200,000,000 Series B with par value of $0.001 per share.

Prior to December 31, 2009 the Company reported as a Shell Company. Steps were taken to correct this error after the Immunotech Laboratories, Inc. reverse merger and on November 13, 2013 the Company filed an 8-K disclosing the change in Shell Company status. The Company is no longer reporting as a Shell Company.

Immunotech Laboratories Inc. is an organization with its core competency established in developing new novel therapeutic molecules for the treatment of HIV/AIDS and subsequently in developing a Preventive HIV/AIDS Vaccine with follow up booster shots. The potential of immuno-modulators within the global market of existing treatments shows a tremendous growth opportunity, driven by the mutation of ARV resistant viral strains, compliance issues, toxicity and quality of life barriers and not to say the least a prohibitive cost burden on both the micro and macro levels.

Furthermore, Immunotech has taken substantial experimental strides in preparing the framework for its product pipeline whereby in addition to the development of a Preventive HIV/AIDS Vaccine, Immunotech has already completed the needed research for HIV/AIDS Prenatal and Pediatric treatments. We take pride in this work, and believe that our sound scientific platform provides the foundation to create wealth while alleviating a tremendous economic burden and pain from humanity.

Immunotech Laboratories, Inc. operates out of a 1,655 sq. ft. facility located at Monrovia, CA under a 2 year lease expiring on March 31, 2015. All lease payments are current under the lease. The Company currently employs 1 full time individual.

Its primary SIC code is 541711and secondary code is 541990.

Immunotech is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS, Hepatitis C, Multiple Sclerosis and Sexually transmitted indications.

IPF is a peptide molecule that has a strong affinity to bind with the HIV virus' peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system.

In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a triple impact approach behaving as a:

6- novel fusion inhibition treatment (blocking the HIV/AIDS virus's receptors from entering the white blood cells)
7- novel entry inhibition treatment (binding with the trap door of the white blood cell, and preventing molecularly the piercing mechanism of the HIV/AIDS virus's receptors)
8- an immuno-modulator, by increasing the white blood cell count, as well as creating a new generation of white blood cells, that lack the gp41 trap door.

Immunotech in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.

Immunotech will employ several strategies of market penetration, taking into consideration either introducing its product as a:

1- Complimentary treatment along with an anti-retroviral partner Pharmaceutical company with established manufacturing and distribution capabilities, securing a position in the global HAART market.

2- As a mono therapy distributed under a global license. This will eventually lead our product to take on a more significant dominant role in the ARV resistant segment of the HIV/AIDS population, referred to as "salvage therapy".

Harry Zhabilov brings to the organization decades of scientific research, and both regulatory and compliance know-how and experience. Between Harry Zhabilov and Immunotech's management team they average more then twenty years of experience, and exposure to a whole spectrum of organizations in the pharmaceutical, biotech and medical device industries.

Immunotech is organization with its core competency established in developing new novel therapeutic molecules for the treatment of HIV/AIDS (ITV-1) and subsequently in developing:

1- Pediatric HIV/AIDS treatment (ITV-2),
2- Pre-Natal HIV/AIDS treatment (ITV-3)
3- Preventive HIV/AIDS Vaccine (ITV-4)

The potential of immuno-modulators within the global market of existing treatments shows a tremendous growth opportunity,

a) driven by the mutation of ARV resistant viral strains
b) compliance issues
c) toxicity and quality of life barriers
d) prohibitive cost burden on both the micro and macro levels.

Furthermore, Immunotech has taken substantial experimental strides in preparing the framework for its product pipeline whereby in addition to the development of a Preventive HIV/AIDS Vaccine, Immunotech has already completed the needed research for HIV/AIDS Prenatal and Pediatric treatments.

The Company believes that their sound scientific platform provides the foundation to create wealth while alleviating a tremendous economic burden and pain from humanity.

The basis of Immunotech's scientific discoveries is the research of our President, Harry Zhabilov, in which he conducted several laboratory studies exploring the manipulation of the human immune system, specifically targeting HIV/AIDS, and investigating alternate approaches to treatment of the disease. Harry Zhabilov identified a molecule known as Irreversible Pepsin Fraction (IPF). It is believed that IPF, is the actual isolated key to the modulation of the immune system, a substance that is both more effective and far less expensive to produce than other technologies. Currently, studies are being conducted in sequencing IPF protein further in preparation for full pre-clinical studies**.**

World Health Organization (WHO) HIV/AIDS Global Forecast

HIV/AIDS is a global disease and its incidence and mortality have risen systematically. Since 1983, more than 60 million people have been infected with the virus, causing 22 million deaths. According to new estimates from the Joint United Nations Program on HIV/AIDS (UNAIDS) and the WHO, at the end of 2001, 38.6 million adults and 3.2 million children were living with HIV.

Demographic and Socioeconomic Global Impact

HIV/AIDS is expensive to treat, competes with other diseases for economic assistance, and often "crowds out" other worthwhile healthcare programs. HIV/AIDS will cause a bigger loss than any other disease because it is 100% fatal, HIV/AIDS kills adults in their prime.

When AIDS is discussed, most people will associate it with Africa. Currently, two thirds of all cases are in Africa. The next wave is Eurasia, which is at the edge of a huge AIDS explosion. Eurasia may face a more serious humanitarian disaster than that of Africa. It is estimated by the US Corporate Research Institute that by year 2025, AIDS will reduce the annual economic growth rate of India by 40% and China by 33%. Russia's economy will get weaker by 40%. Such results will have a global impact on the world economy.

HIV/AIDS causes financial burdens on local and global economies for treatment and prevention efforts. The American National Information Commission (ANIC) estimates that the number of HIV infected in China will be as high as 15 million by 2010.

UNAIDS/WHO 2006	Estimate	Range
People living with HIV/AIDS in 2006	39.5 million	34.1-47.1 million
Adults living with HIV/AIDS in 2006	37.2 million	32.1-44.5 million
Women living with HIV/AIDS in 2006	17.7 million	15.1-20.9 million
Children living with HIV/AIDS in 2006	2.3 million	1.7-3.5 million
People newly infected with HIV in 2006	4.3 million	3.6-6.6 million
Adults newly infected with HIV in 2006	3.8 million	3.2-5.7 million
Children newly infected with HIV in 2006	0.53 million	0.41-0.66 million
AIDS deaths in 2006	2.9 million	2.5-3.5 million
Adult AIDS deaths in 2006	2.6 million	2.2-3.0 million
Child AIDS deaths in 2006	0.38 million	0.29-0.50 million

Regional statistics for HIV & AIDS, end of 2006

Region	Adults & children living with HIV/AIDS	Adults & children newly infected	Adult prevalence*	Deaths of adults & children
Sub-Saharan Africa	24.7 million	2.8 million	5.9%	2.1 million
North Africa & Middle East	460,000	68,000	0.2%	36,000
South and South-East Asia	7.8 million	860,000	0.6%	590,000
East Asia	750,000	100,000	0.1%	43,000
Oceania	81,000	7,100	0.4%	4,000
Latin America	1.7 million	140,000	0.5%	65,000
Caribbean	250,000	27,000	1.2%	19,000
Eastern Europe & Central Asia	1.7 million	270,000	0.9%	84,000
Western & Central Europe	740,000	22,000	0.3%	12,000
North America	1.4 million	43,000	0.8%	18,000
Global Total	39.5 million	4.3 million	1.0%	2.9 million

HIV/AIDS around the world

The majority of people with HIV, some 95% of the global total, live in the developing world. The proportion is set to grow even further as infection rates continue to rise in countries where poverty, poor health care systems and limited resources for prevention and care fuel the spread of the virus.

MARKET ANALYSIS

Current Treatments in The Market

Products in the market demonstrate side effects which although HIV/AIDS treatments, fail to enhance the quality of life. Both families of NRTIs and NNRTIs are administered orally on a daily basis with strict compliance requirements to the regimen. Non-compliance has caused significant viral mutations to the ARVs. This led to treatment of HIV/AIDS patients with therapeutic combinations, further increasing the burden of adverse reactions and side effects. The closest product on the market with some similarities in the mechanism of action is Enfuviritide T-20 which is administered in an injectable form twice a day. This product's limitations are numerous, ranging from limited production supplies, twice daily injections, serious side effects, price, product stability and eventual HIV viral mutation and resistance. Exhibit D clearly identifies in depth and explains the various treatments currently on the market.

Industry Development

The research development pipeline, is indicative that the future of therapeutics is concentrated in developing different novel treatments then current families of ARVs. Most of these products still imply significant stress on the human body, and do not indicate efficacy in long term treatment, specifically immune to HIV viral mutation. It is important to note that one specific group which demonstrates potential promise are the immune modulators. A major difference with IPF as compared with current development products is the specificity of IPF in its mechanism of action against viral presence, whereas current developmental immunomodulators tend to be general in action. IPF based on clinical and experimental data has demonstrated a mechanism of action indicative of a combination Fusion Inhibitor and Immune Modulator.

Competitive Analysis

Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 up to 1000 million dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with new comers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in

year 2014, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost and eventual viral resistance.

SCIENCE

Immunotech, has as its mission the discovery, and development of innovative and effective drug candidates against a range of life-threatening infectious diseases. Utilizing powerful cell-based high-throughput screening platform, complemented with high-content recombinant viral target assays and rational drug design, scientists at Immunotech profile compounds against clinically relevant resistant pathogens. Many pathogens mutate and become resistant to therapy. It is vital that new drugs cope with this genetic variability and avoid resistance.

Background

Resistance to all commercially available antiretroviral (ARV) agents within all classes has been reported. The occurrence of multi-class resistance remains high, with 20% of infected individuals developing resistance to two or more classes within six years of initiating treatment, and 10% of newly diagnosed infections already resistant to at least one class in the U.S. Multi-class resistance is even more prevalent in disenfranchised patient populations, whose rates of successful adherence to even the most simplified regimens available remains prohibitively low. Inactivated Pepsin Fraction (IPF), like other natural autoantibody based fractionated proteins, has an affinity to pathogenic binding and simultaneously produces effects of immune homeostasis. IPF has shown significant antiretroviral activity via immune stimulatory pathways in vitro, notably helper T1 cells elaborate cytokines INFy, IL-2. These cells selectively promote cell-mediated immune responses that are disadvantageous to viral replication.

Methods

Flow cytometric analysis of these cells was conducted using DC monoclonal antibodies and Annexin-V. A Biacore assay system that measures changes in the surface mass concentration was used to determine interactions between IPF molecules and CD4+ cells. Changes were expressed in resonance units (RU), with one RU representing a change in concentration of 1 pg/ mm. T cells were purified from peripheral blood mononuclear (PBMC) cells using anti-body coated magnetic beads.

Results

IPF is able to mediate maturation of dendrites cells in vitro, as determined by up-regulation of MHC class-ll, CD86 and CD83 molecules, regulate pro-inflammatory cytokines IL-12 and INFy, and enhanced T-cells stimulatory capacity. Observable characteristics include modulation of complement activation, saturation of Fc receptors on macrophages, and suppression of various inflammatory mediators, including cytokines and chemokines. IPF demonstrated increased synthesis of Th-1 cells. IPF displayed spontaneous binding with gp41 when prepared for gel electrophoresis, and subsequent fusion inhibition of HIV with CD4+ cells and increased gp41 and gp120 antigenic activity. Virus-specific CD8 cells were stimulated. Flow cytometric analysis revealed apoptosis in CD4+ cells and stimulation of virus-specific CD8 cells.

Conclusions

IPF appears to modulate helper T1 cells' expression of elaborate cytokines INFy, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host's immunologic response to HIV infection. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class l MHC- proteins. IPF appears to present a novel mechanism to reduce viral burden and stimulate innate immune responses to the virus for patients with significant antiretroviral resistance.

Research & Product Portfolio

Scientific and Research Background

IPF is a highly purified pepsin protein extract. IPF has been extensively studied for its safety as well as for its immune modulation characteristics both in animals and human subjects. These immune modulation characteristics of IPF as well as its ability to treat HIV/AIDS patients has demonstrated the unique characteristics of IPF, in being a very highly purified single Pepsin protein extract which has very high Immune modulating characteristics. HIV/AIDS patients treated with IPF demonstrate a rapid modulation of the patients immune system, in a very short period of time (4 - 8 weeks), and does not require extensive administration of IPF.

Product Viability - Mechanism of Action of IPF

The mechanism by which IPF is believed to work is in sharp contrast to currently available HIV treatments. The presently marketed RTI's and PI's (indicated and explained in Exhibit D) work by blocking different steps in viral replication or, in the case of Fuzeon (an example of a competitive product), viral fusion. These regimens produce good initial results, but the ARVs are all susceptible to viral mutations which inherently result in eventual resistance to treatment by the HIV virus. IPF does not just target the HIV virus directly, but it stimulates and induces an aggressive immune response to infected cells and is less likely susceptible to viral resistance.

Current Status - Pharmaceutical Research

Current treatment modalities against HIV usually involve reverse transcriptase inhibitors and protease inhibitors in combination in order to delay viral resistance. Compliance often becomes difficult as (1) the complexity of dosing increases, (2) combinations of medications increase the side effects, and (3) combination therapies dramatically increase the costs associated with treatment.

Product Potential – Scientific & Medical Perspective

The biological activity of IPF "in vivo" has been studied in healthy animals (mice, rats, and rabbits). The animals were injected with IPF equivalent to human IPF dose on an mg-per-kg-body weight. The morphological investigation of the regional lymph nodes and thymus glands of these animals shows active

germinal centers into the cortical follicles and medullar plasmacytosis. The immunological investigation of the sera from those treated animals does not show antibody formation against IPF.

Product Potential and Product Pipeline - Comparison to other Treatments

When comparing IPF as a product to existing treatment modalities, some striking differences become apparent:

(1) The data accumulated to date has shown that IPF is free from the major neurological, gastrointestinal, and hematological side effects seen in the anti-retrovirals in use today or the leading drugs in development;
(2) IPF has not shown to be subject to viral resistance after 18 months of use;
(3) Unlike existing treatments that must be taken on a daily basis, IPF demonstrates lasting efficacy 18 months after a two eight-week treatment period.

Because IPF is dosed for only a total of sixteen weeks, this treatment should be viewed favorably by major governmental and private health care providers for its cost effectiveness.

MARKETING PLAN

MARKETING PLAN SYNOPSIS

Product Differentiation – Compliance Factor – Economic factor

IPF is a cost-effective, immune-based therapy with limited side effects that appears to function in some regards as a therapeutic vaccine vs. ARVs which carry significant side effects and toxicity issues, require daily dosing indefinitely, have compliance problems, are expensive, and are prone to the HIV virus forming resistance. While not clinical markers, these are issues of critical importance to the development and approval process- from an epidemiological perspective, and from the patients' themselves.

Based on our apparent mechanism of action, we believe that we may be modulating an immune response to destroy infected CD4s, which would account for initial decreases. However, we also see a gradual leveling off of CD4, which may in fact alter the overall "count". We believe that with the recombinant form of IPF as a salvage therapy targeting a focused market of ARV resistant patients globally, we believe our product will exploit the established guidelines for HIV/AIDS products with patient population most in need. The size of the salvage market is not insubstantial. Ten to 20% or more of patients on HAART in the USA and EU are resistant to all three classes of ARVs; 70-80% are resistant to one or more. Treatment-naïve subjects are also characterized by 18-22% showing resistance to one or more ARV classes (Rapid Report, XIII International HIV Drug Resistance Workshop, June 2004 / "An update on HIV drug resistance in the United Kingdom" CDR Weekly, Vol 14, no 48). On this indication alone, we estimate 180,000 to 288,000 potential patients available in the USA and EU alone. At an average annual cost of $ 10,000 to $ 20,000 for ARVs, this niche alone is a $ 1.8 to 2.2 billion annual opportunity.

Going forward, we will continue to build the case for the recombinant product as a therapeutic vaccine possibly useful as a method of deferring HAART and possibly creating a state of "long term non-progression".

In summation our product's differentiation is based on:

7- Minimal and minor side effects
8- Zero toxicity issues
9- Tremendous cost savings
10- Short and limited treatment cycle
11- Easier Compliance adherence
12- Zero risk of viral resistance and mutation

PRODUCT SWOT ANALYSIS

Strengths	Minimal and minor side effects Zero toxicity Individual Cost savings Institutional & Governmental Cost savings Short treatment cycle Easy compliance viral resistance or mutation Improving quality of life Improving HIV resource Productivity
Weaknesses	Product requires refrigeration for storage.

Opportunities	Initial marketing based on complimentary treatment Potential to evolve into stand-alone treatment Entry into HIV/AIDS salvage market Potential for Preventive Aids Vaccine Potential to develop yearly vaccine booster shots
Threats	Currently there are no direct competitor either currently in the market or in the research product line, being first to the market is crucial

TECHNOLOGIES SUMMARY

Immunotech has a strong technology and patent position through its own efforts as well as through in-licensed technology and OEM product development agreements. In total, Immunotech products will be protected by numerous issued patents, pending patents and others under preparation. It is anticipated that additional patents will be applied for as the novel products are finalized and then expanded to include additional applications.

Title	U.S. Patent Number/Application Number
IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME FOR DETECTING, PREVENTING, AND TREATING HIV	12/321,262
IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME FOR DETECTING, PREVENTING, AND TREATING HIV	7,479,538

Country	Title	Application Number
Canada	IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THIS FRAGMENT FOR DETECTING, PREVENTING, AND TREATING HIV	2,634,589
Hong Kong	IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THIS FRAGMENT FOR DETECTING, PREVENTING, AND TREATING HIV	08102808.0 / us 11/177,427
Mexico		MX/a/2010/001901

Part D Management Structure and Financial Information

Item 11 The name of the chief executive officer, members of the board of directors, as well as control persons.

Please give a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Officers and Directors. In responding to this item, please provide the following information for each of the issuer's executive officers, directors, general partners and control persons, as of the date of this information statement:

1. Full name; Harry H. Zhabilov

2. Business address; 120 W Pomona Ave Monrovia California

3. Employment history (which must list all previous employers for the past 5 years, positions held, responsibilities and employment dates)

Nov 2006 – Present Immunotech Laboratories Inc. President Pasadena California

Sep 2003 – Sep 2006 Viral Genetics, Inc., Azusa, CA Executive Vice President of Research and Development

4. Board memberships and other affiliations;

2005-Present Member of American Chemical Society (ACS)

2004-Present Member of the Science Advisory Board

2000-Present Member of American Institute of Chemical Engineers (AlChE)

5. Compensation by the issuer; Employment agreement to serve as President with salary of $290,000 per year currently payments are being deferred but expense is being accrued on the financials.

6. Number and class of the issuer's securities beneficially owned by each such person.

Series A Preferred 44,000,000 shares

Series B Preferred 190,000,000 shares

Common Shares 805,000

Common Shares owned by Diamond Investment for the benefit of Harry H. Zhabilov 5,400,000

1. Full Name; Valentine Iordanov Dimitrov

2. Business address; Nishava 61 STR. Sofia Bulgaria

3. Employment History (which must list all previous employers for the past 5 years, positions held, responsibilities and employment dates)

2003-present	"Bulgarian Association of Chemical and Fertilizer Industry" – Chairman
2007-present	"Vital-Fe" LTD – Distribution of bio-technology and pharmaceutical products –Director

4. Board memberships and other affiliations; None

5. Compensation by the issuer; $7,500.00 per month payable in Common Stock issued at a 50% discount to market.

6. Number and class of the issuer's securities beneficially owned by each such person.

None

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; None

Or;

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities. None

C. Disclosure of Family Relationships. Describe any family relationships among and between the issuer's directors, officers, persons nominated or chosen by the issuer to become directors or officers, or

beneficial owners of more than five percent (5%) of the any class of the issuer's equity securities.

On January 30, 2009 the Company entered into a licensing agreement wherein the Company received a license from the Zhabilov Trust for use of the patents underlying use of IPF in treatment of HIV/AIDS only. The licensing agreement provided for Harry Zhabilov to receive 41.5% each of an interest in Immunotech Laboratories, Inc.

On September 14, 2012 the Company created a Preferred Class of 200,000,000 Series B with par value of $0.001 per share. Of these authorized shares Harry Zhabilov was issued 190,000,000 shares. This is in addition to the 44,000,000 shares of Preferred Class Series A issued to Harry Zhabilo in September of 2012. Harry H. Zhabilov is the President of Immunotech and the Trust is set up for the benefit of his children.

D. Disclosure of Related Party Transactions. Describe any transaction during the issuer's last two full fiscal years and the current fiscal year or any currently proposed transaction, involving the issuer, in which (i) the amount involved exceeds the lesser of $120,000 or one percent of the average of the issuer's total assets at year-end for its last three fiscal years and (ii) any related person had or will have a direct or indirect material interest. Disclose the following information regarding the transaction:

1. The name of the related person and the basis on which the person is related to the issuer;

On January 30, 2009 the Company entered into a licensing agreement wherein the Company received a license from the Zhabilov Trust for use of the patents underlying use of IPF in treatment of HIV/AIDS only. The licensing agreement provided for Harry Zhabilov to receive 41.5% each of an interest in Immunotech Laboratories, Inc.

Harry H. Zhabilov is the President of Immunotech and the Trust is set up for the benefit of his children.

The Trust is to receive a payment of $1,500,000 as cash flow permits for the exclusive licensing agreement.

Harry H. Zhabilov is guarantor on the Company lease for the Laboratory Facilities. The monthly rent is $1,650.00 and the lease terminates on March 31, 2015.

2. The related person's interest in the transaction;

None

3. The approximate dollar value involved in the transaction (in the case of indebtedness, disclose the largest aggregate amount of principal outstanding during the time period for which disclosure is required, the amount thereof outstanding as of the latest practicable date, the amount of principal and interest paid during the time period for which disclosure is required, and the rate or amount of interest payable on the indebtedness);

The Company owes $1,500,000 to the Trust for the Licensing agreement.

4. The approximate dollar value of the related person's interest in the transaction;

None, as Harry Zhabilov is not a beneficiary

and

5. Any other information regarding the transaction or the related person in the context of the transaction that is material to investors in light of the circumstances of the particular transaction.

None

Instruction to paragraph D of Item 11:

1. For the purposes of paragraph D of this Item 11, the term "related person" means any director, executive officer, nominee for director, or beneficial owner of more than five percent (5%) of any class of the issuer's equity securities, immediate family members of any such person, and any person (other than a tenant or employee) sharing the household of any such person.

2. For the purposes of paragraph D of this Item 11, a "transaction" includes, but is not limited to, any financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) or any series of similar transactions, arrangements or relationships.

3. The "amount involved in the transaction" shall be computed by determining the dollar value of the amount involved in the transaction in question, which shall include:

a. In the case of any lease or other transaction providing for periodic payments or installments, the aggregate amount of all periodic payments or installments due on or after the beginning of the issuer's last fiscal year, including any required or

D. Disclosure of Related Party Transactions. Describe any transaction during the issuer's last two full fiscal years and the current fiscal year or any currently proposed transaction, involving the issuer, in which (i) the amount involved exceeds the lesser of $120,000 or one percent of the average of the issuer's total assets at year-end for its last three fiscal years and

(ii) any related person had or will have a direct or indirect material interest. Disclose the following information regarding the transaction:

1. The name of the related person and the basis on which the person is related to the issuer;

None

2. The related person's interest in the transaction;

None

3. The approximate dollar value involved in the transaction (in the case of indebtedness, disclose the largest aggregate amount of principal outstanding during the time period for which disclosure is required, the amount thereof outstanding as of the latest practicable date, the amount of principal and interest paid during the time period for which disclosure is required, and the rate or amount of interest payable on the indebtedness);

None

4. The approximate dollar value of the related person's interest in the transaction;

None

and

5. Any other information regarding the transaction or the related person in the context of the transaction that is material to investors in light of the circumstances of the particular transaction.

None

Instruction to paragraph D of Item 11:

1. For the purposes of paragraph D of this Item 11, the term "related person" means any director, executive officer, nominee for director, or beneficial owner of more than five percent (5%) of any class of the issuer's equity securities, immediate family members of any such person, and any person (other than a tenant or employee) sharing the household of any such person.

2. For the purposes of paragraph D of this Item 11, a "transaction" includes, but is not limited to, any financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) or any series of similar transactions, arrangements or relationships.

3. The "amount involved in the transaction" shall be computed by determining the dollar value of the amount involved in the transaction in question, which shall include:

a. In the case of any lease or other transaction providing for periodic payments or installments, the aggregate amount of all periodic payments or installments due on or after the beginning of the issuer's last fiscal year, including any required or

b. The transaction involves services as a bank depositary of funds, transfer agent, registrar, trustee under a trust indenture, or similar services; or

c. The interest of the related person arises solely from the ownership of a class of equity securities of the issuer and all holders of that class of equity securities of the issuer received the same benefit on a pro rata basis.

8. Include information for any material underwriting discounts and commissions upon the sale of securities by the issuer where any of the specified persons was or is to be a principal underwriter or is a controlling person or member of a firm that was or is to be a principal underwriter.

E. Disclosure of Conflicts of Interest. Describe any conflicts of interest. Describe the circumstances, parties involved and mitigating factors for any executive officer or director with competing professional or personal interests.

Item 12. Financial information for the issuer's most recent fiscal period.

Instruction to Item 12: The issuer shall post the financial statements required by this Item 12 through

www.OTCIQ.com under the appropriate report name for the applicable period end. (If the financial statements relate to a fiscal year end, publish it as an “Annual Report,” or if the financial statements relate to a quarter end, publish it as a “Quarterly Report” or “Interim Report”) The issuer must state in its disclosure statement that such financial statements are incorporated by reference. The issuer must also (i) provide a list in the disclosure statement describing the financial statements that are incorporated by reference, (ii) clearly explain where the incorporated documents can be found, and (iii) provide a clear cross-reference to the specific location where the information requested by this Item 12 can be found in the incorporated documents.

The issuer shall provide the following financial statements for the most recent fiscal period (whether fiscal quarter or fiscal year).

1) balance sheet;

2) statement of income;

3) statement of cash flows;

4) statement of changes in stockholders’ equity (for Annual Reports only);

5) financial notes; and

6) audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with generally accepted accounting principles (GAAP) by persons with sufficient financial skills. Information contained in annual financial statements will not be considered current more than 90 days after the end of the issuer’s fiscal year immediately following the fiscal year for which such statement are provided, or with respect to quarterly financial statements, more than 45 days after the end of the quarter immediately following the quarter for which such statements are provided.

Item 13 Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.

Item 14 Beneficial Owners.

Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%) of any class of the issuer's equity securities.

Harry H. Zhabilov, 120 W Pomona Ave Monrovia, CA 91016

Series A Preferred 44,000,000 Shares

Series B Preferred 190,000,000 Shares

MT Rose Corporation PO Box 146, Road Town, Tartola, British Virgin Islands Chrisos Hrizostomoy Cypress Island

200,000,000 Common shares

To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Item 15 The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to operations, business development and disclosure:

1. Investment Banker

None

2. Promoters

None

3. Counsel

Kagel Law, a Professional Corporation

1801 Century Park East, Ste 1201

Los Angeles 90067

310-993-2129

4. Accountant or Auditor - the information shall clearly (i) describe if an outside accountant provides audit or review services, (ii) state the work done by the outside accountant and (iii) describe the responsibilities of the accountant and the responsibilities of management (i.e. who audits, prepares or reviews the issuer's financial statements, etc.). The information shall include the accountant's phone number and email address and a description of the accountant's licensing and qualifications to perform such duties on behalf of the issuer.

None

5. Public Relations Consultant(s)

Blaine Nabors
Nabors Group
13468 Sage Meadow Ln
Valley Center, CA 92082
President/CEO
(713) 875-9200

6. Investor Relations Consultant

None

7. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement - the information shall include the telephone number and email address of each advisor.

None

Item 16 Management's Discussion and Analysis or Plan of Operation.

Instructions to Item 16

Issuers that have not had revenues from operations in each of the last two fiscal years, or the last fiscal year and any interim period in the current fiscal year for which financial statements are furnished in the disclosure statement, shall provide the information in paragraphs A and C of this item. All other issuers shall provide the information in paragraphs B and C of this item.

The discussion and analysis shall focus specifically on material events and uncertainties known to management that would cause reported financial information not to be necessarily indicative of future operating results or of future financial condition.

Issuers are not required to supply forward-looking information. This is distinguished from presently known data that will impact upon future operating results, such as known future increases in costs of labor or materials. This latter data may be required to be disclosed.

A. Plan of Operation.

1. Describe the issuer's plan of operation for the next twelve months. This description should include such matters as:

i. a discussion of how long the issuer can satisfy its cash requirements and whether it will have to raise additional funds in the next twelve months; Cash on hand at December 31, 2013 and 2012 was $633 and $489 respectively. Immunotech is a development stage company whose success depends on the Company's ability to commercializing the treatments currently being tested. The Company has low monthly overhead but the cost of field and clinical test needed to gain Government approval will require that additional funds be raised. There is no guarantee that these amounts will be financed but Management believes that the viability of the product will continue to attract investors.

ii. a summary of any product research and development that the issuer will perform for the term of the plan;

Scientific and Research Background

IPF is a highly purified pepsin protein extract. IPF has been extensively studied for its safety as well as for its immune modulation characteristics both in animals and human subjects. These immune modulation characteristics of IPF as well as its ability to treat HIV/AIDS patients has demonstrated the unique characteristics of IPF, in being a very highly purified single Pepsin protein extract which has very high Immune modulating characteristics. HIV/AIDS patients treated with IPF demonstrate a rapid modulation of the patients immune system, in a very short period of time (4 - 8 weeks), and does not require extensive administration of IPF.

Product Viability - Mechanism of Action of IPF

The mechanism by which IPF is believed to work is in sharp contrast to currently available HIV treatments. The presently marketed RTI's and PI's (indicated and explained in Exhibit D) work by blocking different steps in viral replication or, in the case of Fuzeon (an example of a competitive product), viral fusion. These regimens produce good initial results, but the ARVs are all susceptible to viral mutations which inherently result in eventual resistance to treatment by the HIV virus. IPF does not just target the HIV virus directly, but it stimulates and induces an aggressive immune response to infected cells and is less likely susceptible to viral resistance.

Current Status - Pharmaceutical Research

Current treatment modalities against HIV usually involve reverse transcriptase inhibitors and protease inhibitors in combination in order to delay viral resistance. Compliance often becomes difficult as (1) the complexity of dosing increases, (2) combinations of medications increase the side effects, and (3) combination therapies dramatically increase the costs associated with treatment.

Product Potential – Scientific & Medical Perspective

The biological activity of IPF "in vivo" has been studied in healthy animals (mice, rats, and rabbits). The animals were injected with IPF equivalent to human IPF dose on an mg-per-kg-body weight. The morphological investigation of the regional lymph nodes and thymus glands of these animals shows active germinal centers into the cortical follicles and medullar plasmacytosis. The immunological investigation of the sera from those treated animals does not show antibody formation against IPF.

Product Potential and Product Pipeline - Comparison to other Treatments

When comparing IPF as a product to existing treatment modalities, some striking differences become apparent:

(1) The data accumulated to date has shown that IPF is free from the major neurological, gastrointestinal, and hematological side effects seen in the anti-retrovirals in use today or the leading drugs in development;

(2) IPF has not shown to be subject to viral resistance after 18 months of use;

(3) Unlike existing treatments that must be taken on a daily basis, IPF demonstrates lasting efficacy 18 months after a two eight-week treatment period.

Because IPF is dosed for only a total of sixteen weeks, this treatment should be viewed favorably by major governmental and private health care providers for its cost effectiveness.

FDA approval process is based on The Food and Drug Administration's Strategic Action Plan for Risk Communication is an initiative to tell consumers how the agency makes decisions on the safety and effectiveness of FDA-regulated products. This is the first in a series of articles about the data and methods—and their limitations—that FDA uses to determine whether products are safe for patients and consumers to use.

This is how the agency's Center for Drug Evaluation and Research evaluates the safety and effectiveness of drugs.

iii. any expected purchase or sale of plant and significant equipment;

None

and

iv. any expected significant changes in the number of employees.

None

B. Management's Discussion and Analysis of Financial Condition and Results of Operations.

1. Full fiscal years. Discuss the issuer's financial condition, changes in financial condition and results of operations for each of the last two fiscal years. This discussion should address the past and future financial condition and results of operation of the issuer, with particular emphasis on the prospects for the future. The discussion should also address those key variable and other qualitative and quantitative factors that are necessary to an understanding and evaluation of the issuer. If material, the issuer should disclose the following:

i. Any known trends, events or uncertainties that have or are reasonably likely to have a material impact on the issuer's short-term or long-term liquidity;

None

ii. Internal and external sources of liquidity;

Immunotech has not received approval for the sale of its treatments by the regulatory Agencies and therefor does not have any internal source of liquidity at this stage. Management believes that its current lenders and investors will continue to support its efforts and that based on the current achievements to date the Company may be able to attract additional new lenders and investors as the products are continually tested.

iii. Any material commitments for capital expenditures and the expected sources of funds for such expenditures;

None

iv. Any known trends, events or uncertainties that have had or that are reasonably expected to have a material impact on the net sales or revenues or income from continuing operations;

Colorado has passed a law called “Choice” which allows a patient to choose to take a non-approved drug if there is a doctor willing to administer it which could generate sales in that state.

v. Any significant elements of income or loss that do not arise from the issuer's continuing operations;

None

vi. The causes for any material changes from period to period in one or more line items of the issuer's financial statements;

Cost of Sales decreased by $670,019 to $533,080 on December 31, 2013 from $1,203,099 reported for the same period in 2014. This decrease was due to the Company’s efforts in 2014 to initiate the clinical testing in Bulgaria through its minority owned subsidiary Immunoitech Laboritories BG. The cost was paid through the issuance of shares for services.

Interest Expenses increased by $22,668 during the period ending on December 31, 2013 as a result of interest being accrued on balances due to Shareholders for monies loaned to the Company.

and

vii. Any seasonal aspects that had a material effect on the financial condition or results of operation.

None

2. Interim Periods. Provide a comparable discussion that will enable the reader to assess material changes in financial condition and results of operations since the end of the last fiscal year and for the comparable interim period in the preceding year.

C. Off-Balance Sheet Arrangements.

1. In a separately-captioned section, discuss the issuer’s off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the issuer's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. The disclosure shall include the items specified in paragraphs C(1)(i), (ii), (iii) and (iv) of this Item 16 to the extent necessary to an understanding of such arrangements and effect and shall also include such other information that the issuer believes is necessary for such an understanding.

i. The nature and business purpose to the issuer of such off-balance sheet arrangements;

None

ii. The importance to the issuer of such off-balance sheet arrangements in respect of its liquidity, capital resources, market risk support, credit risk support or other benefits;

None

iii. The amounts of revenues, expenses and cash flows of the issuer arising from such arrangements; the nature and amounts of any interests retained, securities issued and other indebtedness incurred by the issuer in connection with such arrangements; and the nature and amounts of any other obligations or liabilities (including contingent obligations or liabilities) of the issuer arising from such arrangements that are or are reasonably likely to become material and the triggering events or circumstances that could cause them to arise;

None

and

iv. Any known event, demand, commitment, trend or uncertainty that will result in or is reasonably likely to result in the termination, or material reduction in availability to the issuer, of its off-balance sheet arrangements that provide material benefits to it, and the course of action that the issuer has taken or proposes to take in response to any such circumstances.

None

2. As used in paragraph C of this Item 16, the term off-balance sheet arrangement means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the issuer is a party, under which the issuer has:

i. Any obligation under a guarantee contract that has any of the characteristics identified in paragraph 3 of FASB Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others (November 2002) ("FIN 45"), as may be modified or supplemented, and that is not excluded from the initial recognition and measurement provisions of FIN 45 pursuant to paragraphs 6 or 7 of that Interpretation;

None

ii. A retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets;

None

iii. Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument, except that it is both indexed to the issuer's own stock and classified in stockholders' equity in the issuer's statement of financial position, and therefore excluded from the scope of FASB Statement of Financial Accounting Standards No. 133, Accounting for Derivative Instruments and Hedging Activities (June 1998), pursuant to paragraph 11(a) of that Statement, as may be modified or supplemented;

None

or

iv. Any obligation, including a contingent obligation, arising out of a variable interest (as referenced in FASB Interpretation No. 46, Consolidation of Variable Interest Entities (January 2003), as may be modified or supplemented) in an unconsolidated entity that is held by, and material to, the issuer,

where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with, the issuer.

None

Instructions to paragraph C of Item 16

i. No obligation to make disclosure under paragraph C of this Item 16 shall arise in respect of an off-balance sheet arrangement until a definitive agreement that is unconditionally binding or subject only to customary closing conditions exists or, if there is no such agreement, when settlement of the transaction occurs

In satisfying the requirements of paragraph C of this Item 16, the discussion of off-balance sheet arrangements need not repeat information provided in the footnotes to the financial statements, provided that such discussion clearly cross-references to specific information in the relevant footnotes and integrates the substance of the footnotes into such discussion in a manner designed to inform readers of the significance of the information that is not included within the body of such discussion.

Part E Issuance History

Item 17 List of securities offerings and shares issued for services in the past two years.

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer (1) within the two-year period ending on the last day of the issuer's most recent fiscal year and (2) since the last day of the issuer's most recent fiscal year.

The list shall include all offerings of securities, whether private or public, and shall indicate:

(i) The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

None. All shares issued in all periods were exempt transactions. Shares were issued directly from the Company to the service provider.

(ii) Any jurisdictions where the offering was registered or qualified;

None.

(iii) The number of shares offered;

None. All issuances were for services rendered to the individuals providing the services.

(iv) The number of shares sold;

None. The number of shares issued for services in the period ending December 31, 2012 at par $.001 were 119,889,852. The number of shares issued for the 49% interest in Immunotech Bulgaria in the year ending December 31, 2012 were 200,060,000 at a price of $.0001.

The number of shares issued at par, $.001, in the year ended December 31, 2013 for the clinical trial cost in Bulgaria were 19,322,222.

(v) The price at which the shares were offered, and the amount actually paid to the issuer;

None. Shares were issued for services rendered.

(vi) The trading status of the shares;

Not Applicable. All shares were issued with Restrictive Legends. No Legends have been removed for any of the shares issued in the years ended December 31, 2013 or December 31, 2012.

and

(vii) Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

None. All shares were issued for services have legends in accordance with the Securities Act stating that the shares have not been registered.

The list shall also include all shares or any other securities or options to acquire such securities issued for services in the past two fiscal years and any interim periods, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities.

No shares were issued during the Interim period ending March 31, 2014

In the year ending December 31, 2013 the Company issued the following shares for services rendered during the period to the listed entities. All issuances were exempt transactions and all shares were issued with restrictive legends. The shares were issued under the jurisdiction of the State of Nevada.

Dimitar Savov October 2013 shares issued 19,322,222 Field Trial Cost at a per shares basis of $ .003101

In the year ending December 31, 2012 the Company issued the following Common Shares for services rendered during the period in exempt transactions to the listed entities;

MT Rose Corporation May through September 2012 shares issued 200,060,000 for services rendered in association with placement of director and clinical trials in Bulgaria.

Serzhik Kirakosyan June 2012 shares issued 50,000,000 for services rendered.

Daniel Valchanov May 2012 shares issued 3,053,570 for services rendered.

Maurice Nazarian September 2012 shares issued 1,502,995 for services rendered.

Sumeet Lall September 2012 shares issued 10,000,000 for services rendered.

Harry H. Zhabilov July 2012 shares issued 1,502,995 for services rendered.

Roger Pawson July 2012 shares issued 6,000,000 for services rendered.

Ara V. Yaghijian July and August 2012 shares issued 11,490,500 for services rendered.

Dimitar Savov September 2012 shares issued 15,008,500 for services rendered.

Reed Wallace September 2012 shares issued 1,503,000 for services rendered.

Mariya Radivoeva September 2012 shares issued 5,005,030 for services rendered.

Green Electricity September 2012 shares issued 1,639,586 for services rendered.

Blaine Nabors October 2012 shares issued 150,000 for services rendered.

For Your Information Inc. November 2012 shares issued 7,428,571 for services rendered.

Volden Siderov November 2012 shares issued 3,004,050 for services rendered.

Mandjoukov SJSC November 2012 shares issued 502,000 for services rendered.

Todd Hart 2012 shares issued 500,000 for services rendered.

In the year ending December 31, 2012 the Company issued the following Preferred Shares for services rendered during the period to the listed entities;

Harry H. Zarbilov September 2012 Preferred Series A shares issued 44,000,000 for services rendered.

Harry H. Zhabilov September 2012 Preferred Series B shares issued 190,000,000 for services rendered.

With respect to private offerings of securities, the list shall also indicate the identity of the persons who purchased securities in such private offering; provided, however, that in the event that any such person is an entity, the list shall also indicate (a) the identity of each natural person beneficially owning, directly or indirectly, more than five percent (5%) of any class of equity securities of such entity and (b) to the extent not otherwise disclosed, the identity of each natural person who controlled or directed, directly or indirectly, the purchase of such securities for such entity.

Part F Exhibits

The following exhibits must be either described in or attached to the disclosure statement:

Item 18 Material Contracts.

A. Every material contract, not made in the ordinary course of business, that will be performed after the disclosure statement is posted through www.OTCIQ.com or was entered into not more than two years before such posting. Also include the following contracts:

None

1) Any contract to which directors, officers, promoters, voting trustees, security holders named in the disclosure statement, or the Designated Advisor for Disclosure are parties other than contracts involving only the purchase or sale of current assets having a determinable market price, at such market price;

None

2) Any contract upon which the issuer's business is substantially dependent, including but not limited to contracts with principal customers, principal suppliers, and franchise agreements;

Licensing Agreement with the Trust.

3) Any contract for the purchase or sale of any property, plant or equipment for consideration exceeding 15 percent of such assets of the issuer;

None

or

4) Any material lease under which a part of the property described in the disclosure statement is held by the issuer.

Lease Agreement for Laboratories Facility

B. Any management contract or any compensatory plan, contract or arrangement, including but not limited to plans relating to options, warrants or rights, pension, retirement or deferred compensation or bonus, incentive or profit sharing (or if not set forth in any formal document, a written description thereof) in which any director or any executive officer of the issuer participates shall be deemed material and shall be included; and any other management contract or any other compensatory plan, contract, or arrangement in which any other executive officer of the issuer participates shall be filed unless immaterial in amount or significance.

Harry H. Zhabilov's contract calls for issuance of Options which have not been issued as of today.

C. The following management contracts or compensatory plans need not be included:

1) Ordinary purchase and sales agency agreements;

2) Agreements with managers of stores in a chain organization or similar organization;

3) Contracts providing for labor or salesmen's bonuses or payments to a class of security holders, as such; and

4) Any compensatory plan that is available to employees, officers or directors generally and provides for the same method of allocation of benefits between management and non-management participants

Item 19 Articles of Incorporation and Bylaws.

A. A complete copy of the issuer's articles of incorporation or in the event that the issuer is not a corporation, the issuer's certificate of organization. Whenever amendments to the articles of incorporation or certificate of organization are filed, a complete copy of the articles of incorporation or certificate of organization as amended shall be filed.

B. A complete copy of the issuer's bylaws. Whenever amendments to the bylaws are filed, a complete copy of the bylaws as amended shall be filed. Item 20 Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

Item 20 Purchases of Equity Securities by the Issuer and Affiliated Purchasers

A. In the following tabular format, provide the information specified in paragraph (B) of this Item 20 with respect to any purchase made by or on behalf of the issuer or any "Affiliated Purchaser" (as defined in paragraph (C) of this Item 20) of shares or other units of any class of the issuer's equity securities.

None

ISSUER PURCHASES OF EQUITY SECURITIES

Period	Column (a) Total Number of Shares or Units Purchased	Column (b) Average Price Paid Per share or Unit	Column (c) Total number of shares (or Units) Purchased as Part of a Publicly Announced Plans or Programs	Column (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under Plans or Program
Month #1 (Identify Beginning and Ending Dates)	n/a	n/a	n/a	n/a
Month #2 (Identify Beginning and Ending Dates)	n/a	n/a	n/a	n/a
Month #3 (Identify Beginning and Ending Dates)	n/a	n/a	n/a	n/a
Total	n/a	n/a	n/a	n/a

B. The table shall include the following information for each class or series of securities for each month included in the period covered by the report:

1. The total number of shares (or units) purchased (Column (a)). Include in this column all issuer repurchases, including those made pursuant to publicly announced plans or programs and those not made pursuant to publicly announced plans or programs. Briefly disclose, by footnote to the table, the number of shares purchased other than through a publicly announced plan or program and the nature of the transaction (e.g., whether the purchases were made in open-market transactions, tender offers,

in satisfaction of the company's obligations upon exercise of outstanding put options issued by the company, or other transactions).

2. The average price paid per share (or unit) (Column (b)).

3. The total number of shares (or units) purchased as part of publicly announced repurchase plans or programs (Column (c)).

4. The maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs (Column (d)).

Instructions to paragraphs (B)(3) and (B)(4) of this Item 20:

a. In the table, disclose this information in the aggregate for all plans or programs publicly announced.

b. By footnote to the table, indicate:

i. The date each plan or program was announced;

ii. The dollar amount (or share or unit amount) approved;

iii. The expiration date (if any) of each plan or program;

iv. Each plan or program that has expired during the period covered by the table; and

v. Each plan or program the issuer has determined to terminate prior to expiration, or under which the issuer does not intend to make further purchases.

C. For purposes of this Item 20, “Affiliated Purchaser” means:

1. A person acting, directly or indirectly, in concert with the issuer for the purpose of acquiring the issuer's securities; or

2. An affiliate who, directly or indirectly, controls the issuer's purchases of such securities, whose purchases are controlled by the issuer, or whose purchases are under common control with those of the issuer; provided, however, that “Affiliated Purchaser” shall not include a broker, dealer, or other person solely by reason of such broker, dealer, or other person effecting purchases on behalf of the issuer or for its account, and shall not include an officer or director of the issuer solely by reason of that officer or director's participation in the decision to authorize purchases by or on behalf of the issuer.

Item 21 Issuer's Certifications.

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Harry H. Zhabilov, certify that:

1. I have reviewed this Initial Information Disclosure Statement as of March 31, 2014 of Immunotech Laboratories, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date:

_____

/s/Harry H. Zhabilov

President